Shares of Sweetgreen (SG) snapped back +14.3% to $7.11 on July 17 after a punishing week that saw the stock crater 26% in four sessions — investors had dumped the stock due to fears about a nationwide cyclosporiasis outbreak, an intestinal infection caused by parasites in raw produce that has sickened thousands across the U.S. The rebound appears to be a technical bounce from oversold levels, not a sign the threat has passed. For a company whose entire menu depends on uncooked greens, the stakes are existential in ways competitors don't face.
• No Cases Linked to Sweetgreen, But the Brand Takes the Hit Anyway
Sweetgreen fell a sharp 5.6% on July 15 alone, even though no cases have been linked to the salad chain so far; its stock has tanked over 24% in the last month.
On July 14, the stock declined as much as 13%, marking its largest intraday drop since February. The problem: Bloomberg Intelligence analyst Michael Halen said Sweetgreen could face a greater challenge if lettuce becomes unavailable or prices rise sharply because salads represent a substantial portion of its sales. The CDC reports 1,645 confirmed cases across 34 states, with 141 hospitalizations , and 5,100+ additional illnesses are under review.
• A Company Already Bleeding Before the Outbreak Struck Sweetgreen entered this crisis on shaky ground. Q1 2026 revenue was $161.5 million, a decline of 2.9% year-over-year , while comparable sales declined 12.8%, traffic fell 11.2%, and restaurant-level margin dropped from 17.9% to 10%.
The core business remains unprofitable, and the company has missed Wall Street expectations more often than not since going public.
• Wraps Are the Turnaround Bet — But the Outbreak Could Undercut Them Management's main recovery play is a new wraps menu designed to draw price-sensitive customers. CEO Neman described wraps as the company's "most significant menu expansion in several years," with the lower price point expected to help drive traffic. But wraps still rely on fresh produce — the exact category under national suspicion. If consumers pull back from raw greens for weeks, even a successful product launch stalls.
• Wall Street Was Already Skeptical Before the Scare
The consensus rating is Hold, based on 12 Hold ratings, four Buys, and three Sells, with the majority of analysts not anticipating upside over the next year. At $7.11, the stock sits well below the 52-week high of $16.70 reached last July. The August Q2 earnings report will reveal whether the outbreak dented actual foot traffic — or whether today's bounce is just a dead-cat rally for a chain that can't cook its way out of a produce crisis.